A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer

Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48‐year‐old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and p...

Full description

Saved in:
Bibliographic Details
Published in:The journal of obstetrics and gynaecology research 2021-02, Vol.47 (2), p.833-837
Main Authors: Taira, Yusuke, Shimoji, Yuko, Nakasone, Tadaharu, Arakaki, Yoshihisa, Nakamoto, Tomoko, Kudaka, Wataru, Aoki, Yoichi
Format: Article
Language:English
Subjects:
Allergic rhinitis
Bevacizumab
Breast cancer
Carboplatin
Cervical cancer
Cervix
Chemotherapy
Immunotherapy
Monoclonal antibodies
nasal septal perforation
Ovarian cancer
Paclitaxel
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3449-1b1a604589d83a67fc1d8dd3d5c69105aaebb4cd59a9a47ba85d5b1f1f8f05413
cites cdi_FETCH-LOGICAL-c3449-1b1a604589d83a67fc1d8dd3d5c69105aaebb4cd59a9a47ba85d5b1f1f8f05413
container_end_page 837
container_issue 2
container_start_page 833
container_title The journal of obstetrics and gynaecology research
container_volume 47
creator Taira, Yusuke
Shimoji, Yuko
Nakasone, Tadaharu
Arakaki, Yoshihisa
Nakamoto, Tomoko
Kudaka, Wataru
Aoki, Yoichi
description Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48‐year‐old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.
doi_str_mv 10.1111/jog.14589
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2480575528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2480575528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3449-1b1a604589d83a67fc1d8dd3d5c69105aaebb4cd59a9a47ba85d5b1f1f8f05413</originalsourceid><addsrcrecordid>eNp1kE1PAjEQhhujEUUP_gHTxJOHhZa22-6REEUNCRc5b6ZfZAnsYsti8NdbXPTmXGYm88w7kxehO0oGNMVw1SwHlAtVnKEryrnMiBT5eaoZp5kiMu-h6xhXhFBZUHWJeowxQkZUXqHFGBuIDjce1xBhjaPb7lLauuCbALuqqRPQRmexPmDt9mCqr3YDGqcxBruH2qSZcWFfmbRnjn24QRce1tHdnnIfLZ6f3icv2Ww-fZ2MZ5lhnBcZ1RRycnzcKga59IZaZS2zwuQFJQLAac2NFQUUwKUGJazQ1FOvPBGcsj566HS3ofloXdyVq6YNdTpZjrgiQgoxUol67CgTmhiD8-U2VBsIh5KS8mhg2lqWPwYm9v6k2OqNs3_kr2MJGHbAZ7V2h_-Vyrf5tJP8Bnawefw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2480575528</pqid></control><display><type>article</type><title>A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer</title><source>Wiley</source><creator>Taira, Yusuke ; Shimoji, Yuko ; Nakasone, Tadaharu ; Arakaki, Yoshihisa ; Nakamoto, Tomoko ; Kudaka, Wataru ; Aoki, Yoichi</creator><creatorcontrib>Taira, Yusuke ; Shimoji, Yuko ; Nakasone, Tadaharu ; Arakaki, Yoshihisa ; Nakamoto, Tomoko ; Kudaka, Wataru ; Aoki, Yoichi</creatorcontrib><description>Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48‐year‐old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.</description><identifier>ISSN: 1341-8076</identifier><identifier>EISSN: 1447-0756</identifier><identifier>DOI: 10.1111/jog.14589</identifier><identifier>PMID: 33300217</identifier><language>eng</language><publisher>Kyoto, Japan: John Wiley &amp; Sons Australia, Ltd</publisher><subject>Allergic rhinitis ; Bevacizumab ; Breast cancer ; Carboplatin ; Cervical cancer ; Cervix ; Chemotherapy ; Immunotherapy ; Monoclonal antibodies ; nasal septal perforation ; Ovarian cancer ; Paclitaxel ; Targeted cancer therapy</subject><ispartof>The journal of obstetrics and gynaecology research, 2021-02, Vol.47 (2), p.833-837</ispartof><rights>2020 Japan Society of Obstetrics and Gynecology</rights><rights>2020 Japan Society of Obstetrics and Gynecology.</rights><rights>2021 Japan Society of Obstetrics and Gynecology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3449-1b1a604589d83a67fc1d8dd3d5c69105aaebb4cd59a9a47ba85d5b1f1f8f05413</citedby><cites>FETCH-LOGICAL-c3449-1b1a604589d83a67fc1d8dd3d5c69105aaebb4cd59a9a47ba85d5b1f1f8f05413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33300217$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taira, Yusuke</creatorcontrib><creatorcontrib>Shimoji, Yuko</creatorcontrib><creatorcontrib>Nakasone, Tadaharu</creatorcontrib><creatorcontrib>Arakaki, Yoshihisa</creatorcontrib><creatorcontrib>Nakamoto, Tomoko</creatorcontrib><creatorcontrib>Kudaka, Wataru</creatorcontrib><creatorcontrib>Aoki, Yoichi</creatorcontrib><title>A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer</title><title>The journal of obstetrics and gynaecology research</title><addtitle>J Obstet Gynaecol Res</addtitle><description>Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48‐year‐old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.</description><subject>Allergic rhinitis</subject><subject>Bevacizumab</subject><subject>Breast cancer</subject><subject>Carboplatin</subject><subject>Cervical cancer</subject><subject>Cervix</subject><subject>Chemotherapy</subject><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>nasal septal perforation</subject><subject>Ovarian cancer</subject><subject>Paclitaxel</subject><subject>Targeted cancer therapy</subject><issn>1341-8076</issn><issn>1447-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kE1PAjEQhhujEUUP_gHTxJOHhZa22-6REEUNCRc5b6ZfZAnsYsti8NdbXPTmXGYm88w7kxehO0oGNMVw1SwHlAtVnKEryrnMiBT5eaoZp5kiMu-h6xhXhFBZUHWJeowxQkZUXqHFGBuIDjce1xBhjaPb7lLauuCbALuqqRPQRmexPmDt9mCqr3YDGqcxBruH2qSZcWFfmbRnjn24QRce1tHdnnIfLZ6f3icv2Ww-fZ2MZ5lhnBcZ1RRycnzcKga59IZaZS2zwuQFJQLAac2NFQUUwKUGJazQ1FOvPBGcsj566HS3ofloXdyVq6YNdTpZjrgiQgoxUol67CgTmhiD8-U2VBsIh5KS8mhg2lqWPwYm9v6k2OqNs3_kr2MJGHbAZ7V2h_-Vyrf5tJP8Bnawefw</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Taira, Yusuke</creator><creator>Shimoji, Yuko</creator><creator>Nakasone, Tadaharu</creator><creator>Arakaki, Yoshihisa</creator><creator>Nakamoto, Tomoko</creator><creator>Kudaka, Wataru</creator><creator>Aoki, Yoichi</creator><general>John Wiley &amp; Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>202102</creationdate><title>A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer</title><author>Taira, Yusuke ; Shimoji, Yuko ; Nakasone, Tadaharu ; Arakaki, Yoshihisa ; Nakamoto, Tomoko ; Kudaka, Wataru ; Aoki, Yoichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3449-1b1a604589d83a67fc1d8dd3d5c69105aaebb4cd59a9a47ba85d5b1f1f8f05413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Allergic rhinitis</topic><topic>Bevacizumab</topic><topic>Breast cancer</topic><topic>Carboplatin</topic><topic>Cervical cancer</topic><topic>Cervix</topic><topic>Chemotherapy</topic><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>nasal septal perforation</topic><topic>Ovarian cancer</topic><topic>Paclitaxel</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taira, Yusuke</creatorcontrib><creatorcontrib>Shimoji, Yuko</creatorcontrib><creatorcontrib>Nakasone, Tadaharu</creatorcontrib><creatorcontrib>Arakaki, Yoshihisa</creatorcontrib><creatorcontrib>Nakamoto, Tomoko</creatorcontrib><creatorcontrib>Kudaka, Wataru</creatorcontrib><creatorcontrib>Aoki, Yoichi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>The journal of obstetrics and gynaecology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taira, Yusuke</au><au>Shimoji, Yuko</au><au>Nakasone, Tadaharu</au><au>Arakaki, Yoshihisa</au><au>Nakamoto, Tomoko</au><au>Kudaka, Wataru</au><au>Aoki, Yoichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer</atitle><jtitle>The journal of obstetrics and gynaecology research</jtitle><addtitle>J Obstet Gynaecol Res</addtitle><date>2021-02</date><risdate>2021</risdate><volume>47</volume><issue>2</issue><spage>833</spage><epage>837</epage><pages>833-837</pages><issn>1341-8076</issn><eissn>1447-0756</eissn><abstract>Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48‐year‐old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.</abstract><cop>Kyoto, Japan</cop><pub>John Wiley &amp; Sons Australia, Ltd</pub><pmid>33300217</pmid><doi>10.1111/jog.14589</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1341-8076
ispartof The journal of obstetrics and gynaecology research, 2021-02, Vol.47 (2), p.833-837
issn 1341-8076
1447-0756
language eng
recordid cdi_proquest_journals_2480575528
source Wiley
subjects Allergic rhinitis
Bevacizumab
Breast cancer
Carboplatin
Cervical cancer
Cervix
Chemotherapy
Immunotherapy
Monoclonal antibodies
nasal septal perforation
Ovarian cancer
Paclitaxel
Targeted cancer therapy
title A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-31T23%3A58%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20of%20nasal%20septal%20perforation%20caused%20by%20bevacizumab%20for%20advanced%20cervical%20cancer&rft.jtitle=The%20journal%20of%20obstetrics%20and%20gynaecology%20research&rft.au=Taira,%20Yusuke&rft.date=2021-02&rft.volume=47&rft.issue=2&rft.spage=833&rft.epage=837&rft.pages=833-837&rft.issn=1341-8076&rft.eissn=1447-0756&rft_id=info:doi/10.1111/jog.14589&rft_dat=%3Cproquest_cross%3E2480575528%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3449-1b1a604589d83a67fc1d8dd3d5c69105aaebb4cd59a9a47ba85d5b1f1f8f05413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2480575528&rft_id=info:pmid/33300217&rfr_iscdi=true